RebelBio

RebelBio sources its investments primarily through SOSV's accelerator network, including IndieBio and HAX, which evaluate hundreds of life-science and deep-tech startups annually. This captive pipeline provides access to deals before they reach most institutional investors. The firm also leverages its Princeton and Cork locations to tap into university spinouts and research partnerships (per public record).

RebelBio focuses on pre-seed and seed-stage investments, typically deploying $500K to $2M per initial round. The firm reserves capital for follow-on rounds in high-performing portfolio companies. It often leads or co-leads rounds and operates alongside SOSV's later-stage funds for larger commitments (per public record).

While synthetic biology is a core focus, RebelBio also invests in medical devices, digital health, agricultural biotech, and climate-related technologies that involve biological platforms. The firm explicitly avoids pure software plays or traditional biopharma drug development — it prefers platform technologies that can be applied across multiple verticals (per public record).

RebelBio operates as a dedicated venture fund within the SOSV structure. SOSV is a global venture capital firm managing over $1.5B in assets (per SOSV website) and running multiple thematic funds. RebelBio manages its own investments and GP-led decisions but shares resources, infrastructure, and deal flow with SOSV's other funds (per public record).

RebelBio is one of SOSV's vertical funds alongside IndieBio (life sciences) and HAX (hard tech). Each fund has its own investment thesis and team, but they co-invest and cross-refer opportunities. RebelBio deals are often sourced from IndieBio's accelerator batches, while HAX provides engineering support for hardware-heavy portfolio companies (per public record).